Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mirxes Holding Company Limited ( (HK:2629) ) just unveiled an update.
Mirxes Holding Company Limited announced that its core product, GASTROClear™, has received approval from China’s National Medical Products Administration as a Class III Medical Device for non-invasive gastric cancer screening. This approval marks a significant milestone for the company, allowing it to expand its operations in China and potentially cover a high-risk population of over 500 million adults. The company plans to increase its sales team and production capacity in China to support the commercialization of GASTROClear™.
More about Mirxes Holding Company Limited
Mirxes Holding Company Limited, incorporated in the Cayman Islands, operates in the medical diagnostics industry. The company focuses on in vitro diagnostic tests, with a particular emphasis on innovative cancer screening solutions.
Average Trading Volume: 1,532,402
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$19.55B
See more data about 2629 stock on TipRanks’ Stock Analysis page.